enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference

enGene Therapeutics Inc.

2026-Q1 EPS reported $0.44

Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.
Cash & marketable securities $312.5M; expected runway into 2H 2028.
Expanded Hercules Capital debt facility to $125M for detalimogene development & commercial prep.
LEGEND pivotal cohort 63% CR at any time (n=62); BLA filing planned for 2H 2026.
12-month CR data expected 2H 2026; CDRP program selected by FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

enGene Therapeutics Inc. reported first quarter ended January 31, 2026 results: net income net loss attributable to common shareholders was approximately $29.8 million, EPS $0.44 per share.

Period: first quarter ended January 31, 2026
Net income: net loss attributable to common shareholders was approximately $29.8 million
EPS: $0.44 per share
Result: reported results

Exact text from the filing

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-097534

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.